2014年3月24日，赛默飞世尔和GE Healthcare宣布已经完成了将其若干资产出售予GE Healthcare(GE 医疗）的交易。

　　GE Healthcare收购了赛默飞世尔的细胞培养、基因调节和磁珠业务，购买价格为10.65亿美元。赛默飞剥离该三项业务是为了在收购Life Tech中符合监管规定。

　　GE Healthcare表示，这些业务将成为GE Healthcare集团生命科学事业部的一部分，该项收购使得GE Healthcare扩大其为新药、疫苗的研发制造提供仪器、技术和服务的范围。

　　两家公司首次宣布该交易在今年1月。此三项业务2013年的收入为2.5亿美元。


 

GE completes acquisition of strategic assets from Thermo Fisher Scientific

CHALFONT ST. GILES, UK – 24 March 2014 – GE (NYSE:GE) announced today that it has completed the acquisition of Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses. The acquisition allows GE to expand its offering of tools, technologies and services for the discovery and manufacture of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business.

Commenting on the close, Kieran Murphy, President and CEO of GE Healthcare’s Life Sciences business said, “GE Healthcare has built a world-class set of technologies for the life sciences sector, and these new businesses will strongly enhance our current offerings. As well as providing us with new tools for drug discovery and biomedical research, our customers in biopharmaceutical manufacturing will benefit straight away from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. Through this acquisition we immediately expand our cell culture media production capabilities in Asia, the Americas and Europe, enabling us to offer the biopharmaceutical industry greater confidence in the security of supply of a key part of their production process”.